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Objectives The AMANHI morbidity study aims to quantify and de-
scribe severe maternal morbidities and assess their associations with 
adverse maternal, fetal and newborn outcomes in predominantly ru-
ral areas of nine sites in eight South Asian and sub–Saharan African 
countries.
Methods AMANHI takes advantage of on–going population–based 
cohort studies covering approximately 2 million women of reproduc-
tive age with 1– to 3–monthly pregnancy surveillance to enrol preg-
nant women. Morbidity information is collected at five follow–up 
home visits – three during the antenatal period at 24–28 weeks, 
32–36 weeks and 37+ weeks of pregnancy and two during the post-
partum period at 1–6 days and after 42–60 days after birth. Struc-
tured–questionnaires are used to collect self–reported maternal mor-
bidities including hemorrhage, hypertensive disorders, infections, 
difficulty in labor and obstetric fistula, as well as care–seeking for 
these morbidities and outcomes for mothers and babies. Addition-
ally, structured questionnaires are used to interview birth attendants 
who attended women’s deliveries. All protocols were harmonised 
across the sites including training, implementation and operational-
ising definitions for maternal morbidities.
Importance of the AMANHI morbidity study Availability of reli-
able data to synthesize evidence for policy direction, interventions 
and programmes, remains a crucial step for prioritization and ensur-
ing equitable delivery of maternal health interventions especially in 
high burden areas. AMANHI is one of the first large harmonized pop-
ulation–based cohort studies being conducted in several rural centres 
in South Asia and sub–Saharan Africa, and is expected to make sub-
stantial contributions to global knowledge on maternal morbidity 
burden and its implications.
Electronic supplementary material: 
The online version of this article contains supplementary material.
Pregnancy, childbirth and their related complications present a high lev-
el of risk to the survival, health and well–being of women and their ba-
bies in low and middle income country settings. Maternal mortality is 
the most commonly cited maternal health statistic: approximately 
289 000 women die annually from pregnancy–related causes, 85% of 
these deaths occur in sub–Saharan Africa and South Asia alone [1]. The 
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major direct causes of maternal deaths include hemor-
rhage, infection, unsafe abortion, eclampsia and obstructed 
labor [1–3]. With each maternal death, however, an addi-
tional 20 to 30 women are estimated to suffer acute mor-
bidity and disabilities with substantial impact on their 
physical, psychological, social and economic functioning 
[4–7]. An estimated 15% of all pregnant women, approxi-
mately 20 million women globally, suffer a spectrum of 
maternal illnesses ranging in severity from mild disease to 
acute severe, life–threatening complications or near death 
events [3,8–10]. The challenge is that maternal ill–health 
and its effects are not well defined and seldom measured 
[11]; estimates are imprecise and likely underestimate the 
true burden [2,6,11,12], thereby undermining efforts to 
harness resources to address them.
Most studies on maternal morbidity are facility–based and 
are conducted in developed countries. There are marked 
disparities between developing and developed countries 
with respect to the prevalence of maternal morbidities. This 
could be a function of the higher frequency of childbirth, 
poorer general health of women, lack of care seeking and 
low quality of care available in developing countries. There 
is also a suggestion that women from some geographic re-
gions might carry relatively high risk of maternal morbid-
ity even if their environment is improved. For instance, a 
multi–country study among migrant populations in Aus-
tralia, Canada and Denmark, found that, compared to non–
migrants, migrants from sub–Saharan Africa appeared to 
have higher maternal morbidity risks and these findings 
were consistent with findings from studies conducted in 
Italy, Belgium the Netherlands and the UK [13–18]. In 
low– and middle–income countries (LMICs, especially 
those in sub–Saharan Africa and South Asia where the bur-
den of morbidity is largest), there is a dearth of data on 
morbidity because maternal access to facilities is poor and 
vital registration systems are lacking or incomplete. Facil-
ity–based data are not enough to describe the true burden 
of morbidities but data from the community level, where 
many births and pregnancy–associated complications oc-
cur, are also particularly lacking and the quality of report-
ing is often poor. Prevalence estimates for morbidities are 
based on statistical models with substantial uncertainties 
around them. There is a clear need to generate high qual-
ity and reliable population–based estimates of severe ma-
ternal morbidity using robust epidemiological methods es-
pecially in sub–Saharan Africa and Asia.
The Alliance for Maternal and Newborn Health Improve-
ment (AMANHI) maternal morbidity study directly re-
sponds to this need. The study aims to describe and quan-
tify severe maternal morbidities and assess their associations 
with adverse maternal, fetal and newborn outcomes. It is 
being implemented at nine sites in eight countries of sub–
Saharan Africa and South Asia. The study uses harmonized 
methods to collect prospective population–level maternal 
morbidity data. AMANHI morbidity study, coordinated by 
the Maternal, Newborn, Child and Adolescent Health de-
partment of the World Health Organization (WHO/MCA) 
will contribute to improving estimates of severe maternal 
morbidity; provide a better understanding of the contribu-
tory factors that require consideration when designing in-
terventions; and inform the focus of future interventions 
in order to optimize impact. This manuscript describes the 
protocol for the harmonized implementation of the study.
OBJECTIVES
The objectives are to determine the burden of severe acute 
maternal morbidity, describe the care received by pregnant 
and delivered women, and examine the association of se-
vere maternal morbidity and care received with adverse 
maternal, fetal and neonatal outcomes.
METHODS
Study design and setting
The AMANHI morbidity study is a population–based, pro-
spective cohort study. Trained AMANHI morbidity study 
fieldworkers conduct routine surveillance home visits to 
identify pregnant women, enrol them for follow–up 
through the pregnancy till after 42 days postpartum to col-
lect data on morbidity, care seeking and outcomes for 
mothers and babies including preterm birth, intrauterine 
growth restriction (IUGR), stillbirths and neonatal mortal-
ity. It is built on an existing platform of neonatal health 
studies being implemented in Bangladesh (Sylhet), India 
(Uttar Pradesh), Pakistan (Karachi and Matiari) in south 
Asia; and Democratic Republic of Congo (Equator), Ghana 
(Kintampo), Kenya (Western province), Tanzania (Pemba) 
and Zambia (Southern Province Zambia) in sub–Saharan 
Africa. The study spans a period of 24–36 months, with 
staggered implementation across sites, starting in 2013 and 
expected to end in 2016.
Study population and setting
The AMANHI morbidity study is being implemented in 
predominantly rural populations where women’s educa-
tional levels are low. A summary of the characteristics of 
the study sites is as shown in Table 1. Families mainly en-
gage in subsistence agriculture, petty trading and fishing. 
A variety of health facilities ranging from community clin-
ics (providing only first aid and referral services) to district 
hospitals serve the population. In AMANHI, these health 
facilities were mapped according to their type (health post/
community clinic, health center, district or provincial hos-
pital) and range of services provided (out–patients only; 
basic delivery services; basic or comprehensive emergency 
December 2016  •  Vol. 6 No. 2 •  020601	 2	 www.jogh.org •  doi: 10.7189/jogh.06.020601
V
IE
W
PO
IN
TS
PA
PE
RS
Study protocol on burden of maternal morbidity and adverse birth outcomes
obstetric care). This mapping was done as part of on–go-
ing community–based pregnancy and birth surveillance 
that involves 1– to 3–monthly household visits by trained 
fieldworkers to all women of reproductive age (15 to 49 
years). The exception to the community surveillance is 
Zambia where recruitment is facility–based as explained 
below. With each woman visited at least once every three 
months, pregnancies are identified early and any compli-
cations or adverse outcomes are documented close to when 
they occur. Any woman of reproductive age who resides in 
the study area is eligible for enrolment into the study once 
they fall pregnant and consent to participate. In order to 
generate comparable data that will be amenable to pooled 
analyses, the implementation of the study is harmonised 
across sites as described in the following sections.
Harmonization of protocols and 
implementation strategies
When the study was planned in 2012, investigators from 
all participating sites agreed on common protocols, stan-
dard operating procedures, methods and strategies for im-
plementation.
Protocols
The principal investigators put together an agreed common 
protocol for the study. They developed an initial generic 
protocol from which all the sites developed specific adap-
tations for their sites. These protocols were submitted to 
and approved by ethical review committees of the WHO 
and at the respective sites.
Standard operating procedures & 
implementing strategies
Core variable tables. The AMANHI investigators discussed 
common data to collect and collated these into a core vari-
able table (CVT) to be used across sites (tables in the Online 
Supplementary Document). The table specifies and de-
fines signs and symptoms that are elicited during interviews 
with women, measurements, outcomes and important base-
line variables such as maternal age, education, household 
assets and the format in which these data should be col-
lected and stored across the sites (ie, as text, numeric or 
time/date formats). The variables on this table are included 
in questionnaires that were used across all sites.
Timing and frequency of visits. A uniform schedule for 
household visits by fieldworkers was used across AMANHI 
sites, as shown in Figure 1. Timing and frequency of the 
visits have been chosen to enable detailed information on 
women’s morbidity experiences, within each trimester of 
pregnancy, to be collected close to their occurrence. The 
first visit to the pregnant woman and her household is im-
mediately after enrolment where fieldworkers conduct ba-
sic assets inventory and collect socio–demographic data. 
The first antenatal visit to collect morbidity information 
during pre–pregnancy and in early pregnancy prior to the 
visit is made at 24–28 weeks of pregnancy. Two more 
household visits are made during the antenatal period at 
32–36 weeks and after 37 weeks of gestation to collect data 
on morbidities during the interval between the index and 
the previous visits and any care seeking around the preg-
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Table 1. Summary description of the parent studies, surveillance system, surveillance population and annual number of births at 
AMANHI sites
Site Parent Study title and objective exiSting Pregnancy  
Surveillance SyStem
total 
Surveillance 
PoPulation
reProduc-
tive–aged 
women in 
Surveillance
aP-
Proximate 
annual 
birthS
Bangladesh Etiology of Neonatal Infection in South Asia (ANISA): To estimate 
community level etiology–specific incidence predictive risk factors 
and clinical features, treatment and prevention strategies for serious 
infections among young infants (0–59 days).
2–monthly by trained com-
munity health workers 
(CHWs)
600 000 88 000 13 000
Democratic 
Republic of 
Congo (DRC)
African Neonatal Sepsis Trial (AFRINEST): to test the safety and ef-
ficacy of simplified antibiotic regimens for treating possible serious 
bacterial infection in 0–59 day–old infants
3–monthly by CHWs 699 288 65 000 12 000
Ghana Neonatal vitamin A supplementation (NeovitA) study: to determine 
if vitamin A supplementation to neonates once, orally, <48 hours of 
birth will reduce neonatal, early and late infant mortality
Monthly by fieldworkers 700 000 147 000 21 000
India–Shivgarh Topical emollient application to babies to prevent infection espe-
cially in preterms & ANISA studies
3–monthly by fieldworkers 1 350 000 184 430 44 000
Kenya AFRINEST study: same as DRC 3–monthly by CHWs 400 000 30 000 10 000
Pakistan–Karachi ANISA study: same as Bangladesh 3–monthly by fieldworkers 270 000 63 000 9500
Pakistan–Matiari ANISA study: same as Bangladesh 3–monthly by fieldworkers 215 200 64 000 8000
Tanzania–Pemba Chlorhexidine (CHX) study: to evaluate the efficacy of chlorhexi-
dine cord cleansing on neonatal mortality
6 weekly by trained CHWs 390 000 72 000 14 000
Zambia Chlorhexidine (CHX) study: to evaluate the efficacy of chlorhexi-
dine cord cleansing on neonatal mortality
No pregnancy surveillance; 
facility ANC enrolment
25 000* 25 000 9000
*Zambia to recruit only from antenatal clinics.
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nancy. Sites estimate gestational ages of pregnancies using 
women’s reported date of last normal menstrual period 
(LMP) to plan the antenatal visits. Two additional visits are 
made after delivery; within the first week (days 0–6) and 
after 42 days of birth to collect data on pregnancy out-
comes, morbidities and their outcomes as well as care 
sought for the mother and baby. Measurements of blood 
pressure and urine proteins is made at each of the visits.
Training of trainers for implementation. The WHO/
MCA trained and standardized AMANHI investigators from 
all the sites on the strategy for uniform implementation of 
the study across sites. The training involved the approach 
to consenting, collecting self–reported morbidity, measure-
ment of blood pressure and testing urine for proteins for 
all participants in the study during household visits. Issues 
around confidentiality and sensitivity around eliciting un-
pleasant experiences from families were discussed. The 
complexity of measuring blood pressure within the home 
setting, collecting non–contaminated urine samples and 
ensuring accuracy of the measurements was particularly 
emphasized. Participants were trained to repeat all blood 
pressure (BP) measurements after 30 minutes of the initial 
recording. They discussed protocols for referral of women 
with abnormal findings (such as elevated BP and/or pro-
teinuria) for appropriate care within health facilities. They 
were trained to conduct interviews with birth attendants 
and to review facility records in order to validate women’s 
reported morbidities. During practice sessions, participants 
followed the step–by–step process to practiced BP mea-
surement on each other. Key areas of emphasis during 
training of fieldworkers in the sites were discussed.
Training of data collectors at sites and quality assur-
ance around data collection. The investigators who par-
ticipated in the harmonized training in turn trained study 
fieldworkers at their respective sites for the data collection. 
The study fieldworkers should have secondary/high school 
education (at least 10 years of formal education). The team 
also agreed on a common process for monitoring imple-
mentation and data quality across sites by the WHO/MCA. 
As part of the quality assurance protocol, ranges were spec-
ified for all variables and this was used to check the data. 
Data checks were done both on the field and in the data 
management centres within the respective sites. Inconsis-
tent data are identified and rectified on the field, at the data 
centres or both. In addition, sites send cumulative study 
data to the WHO/MCA on a quarterly basis. Similar range 
and consistency checks are conducted on these data and 
outliers identified. The WHO data manager sends feedback 
to the sites for response and, where indicated, the WHO 
data set is updated accordingly. Trends in outliers and in-
consistent data are analyzed according to the fieldworker 
who collected them and feedback sent to the sites to inform 
re–training of staff.
Study supplies/equipment
Fieldworkers are provided equipment and training to di-
rectly assess pregnant women for hypertensive disorders 
during home visits. Each fieldworker uses urinalysis kits 
(Uristix® by Siemens, Gujarat, India) to assess proteinuria 
and a digital sphygmomanometer (Microlife® WatchBP® 
Home A BP3MX1–3, Widnau, Switzerland) [19,20] to 
measure women’s blood pressure. All these study materials 
were procured from a common source.
Surveillance for pregnancy identification
During home visits, fieldworkers use a variety of methods 
to identify pregnant women. These include direct disclo-
sure by women or eliciting information on missed men-
strual periods from women’s LMPs. When unsure, women 
in Bangladesh, Pakistan (Karachi and Matiari), India (UP) 
and Tanzania (Pemba) had the option to request a urine 
pregnancy test to confirm pregnancies. Zambia is the ex-
ception where, because over 96% of women in the study 
area attend antenatal care (ANC) clinics during pregnancy 
[21], recruitment into AMANHI is done at these ANC clin-
ics. Once a woman is found to be pregnant, an information 
sheet containing a comprehensive summary of the study 
objectives, risks and benefits is read to potential partici-
pants in their local or their preferred language to help them 
make an informed decision to participate in the study. Con-
sented mothers receive a unique study identification num-
ber (study ID).
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Figure 1. Antenatal (AN) and postnatal (PN) follow–up visit schedule–AMANHI morbidity study
AMANHI study group.
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Follow–up on enrolled women
The AMANHI morbidity study employs both active and 
passive surveillance for collecting maternal morbidity data. 
In each site, fieldworkers use structured questionnaires 
(generated from the core variable table) to actively collect 
data on women’s self–reported morbidity and directly assess 
for hypertensive disorders during pregnancy and postpar-
tum visits. As detailed in the next sub–section, questions on 
self–reported morbidity explored programmatically relevant 
morbidity causes such as antepartum hemorrhage, infec-
tions, miscarriage and abortions, signs and symptoms of 
hypertensive disorders of pregnancy such as severe head-
aches, blurred vision among others. For all births, field-
workers also interview birth attendants (in the attendant’s 
home or place of work) to obtain additional details on com-
plications each AMANHI study woman (whose delivery 
they assisted/attended) encounter during labor and delivery. 
Birth attendant account on morbidity will be used as vali-
dation for the women’s self–reported morbidity. The unique 
study ID provided to each enrolled woman links data from 
the two types of forms.
Baseline home visit. At baseline/enrolment fieldworkers 
collect household characteristics and baseline socio–demo-
graphic data on participants. They conduct an assets inven-
tory which is used to classify households into socio–eco-
nomic quintiles. This will be used to evaluate inequities in 
the distribution of severe maternal morbidity in the AMAN-
HI cohort. The fieldworkers also collect data on previous 
medical and obstetric history, history of cigarette smoking 
or alcohol ingestion and morbidity experiences since the 
onset of the pregnancy.
Listings for antenatal visits. Women’s gestational age in-
formation is collected from either self–reported LMP or 
from any record of ultrasound scan conducted by the time 
of the visit. This information is used to estimate the gesta-
tional age of women. Each week, the study team generates 
a listing of women who are due for any of the antenatal vis-
its and grouped into clusters that allow for fieldworkers to 
visit them for morbidity data collection. Whenever a wom-
an is found to be temporarily away at the time of a sched-
uled visit, she is moved to the top of the listings for the next 
week and her visit is given priority and completed first.
Antenatal home visits. During the first antenatal home 
visit (conducted between 24–28 weeks), fieldworkers first 
ascertain the status of the pregnancy (whether woman is 
still pregnant or the pregnancy has terminated) and collect 
data on morbidity experiences. If the woman has com-
menced routine antenatal care (ANC) clinic attendance 
within the routine health system, fieldworkers abstract data 
on morbidity, results of any laboratory investigations (eg, 
hemoglobin level and presence of malaria parasites), ultra-
sound scans and maternal anthropometric measures 
(height, weight, mid upper arm circumference) taken by 
health professionals. At the end of the visit, they measure 
women’s BP and check their urine for proteins.
At subsequent antenatal home visits at 32–36 weeks and 
after 37 completed weeks, the same questionnaire is used 
to collect morbidity data covering the interval between the 
previous and the index visit.
The visit covers collection of reported morbidity and 
screening for hypertensive disorders in pregnancy. Table 2 
shows a summary of data collected at various visits in the 
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Table 2. Summary of data collected at various visits in the AMANHI maternal morbidity study
main category thematic areaS of data collection Source of data viSit and time of data collection
Maternal morbidity 1. Antepartum hemorrhage 1. Maternal self–report Antenatal home visits (24–28 weeks, 
32–36 weeks, 37–40 weeks), postna-
tal home visits (day 1–6 and day 42–
60 after birth), birth attendant inter-
views 0–6 days after birth, health 
facility records
2. Postpartum hemorrhage 2.  Maternal self–report and birth 
attendant interview
3. Hypertensive disorders of pregnancy 3.  Measurements of blood pres-
sure and urine protein at all 
home visits, maternal self–re-
port
4. Difficulty in labor 4.  Maternal self–report and birth 
attendant interview
5. Infection 5. Maternal self–report
6. Obstetric fistula 6. Maternal self–report
Background characteristics Socio–economic, baseline characteristics of the 
woman and her household, including an asset 
inventory
Maternal self–report Baseline home visit at enrolment
Medical history Previous obstetric and gynecological history, 
birth defects, prematurity, stillbirths and IUGR 
among previous babies, previous medical and 
surgical history
Maternal self–reports and health 
facility records
Baseline home visit at enrolment
Risk factors and exposures Cigarette smoking, alcohol ingestion, smoke 
from biomass cooking fuels
Maternal self–reports Baseline home visit at enrolment
Anthropometry Paternal and maternal weights and heights, ma-
ternal mid–upper arm circumference
Health facility records All antenatal and postnatal home visits
Screening for hypertensive 
disorders of pregnancy
Measurement of blood pressure and testing 
urine for proteins
Direct measurement during home 
visits
All visits except delivery visits
Study protocol on burden of maternal morbidity and adverse birth outcomes
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AMANHI maternal morbidity study. Details on the process 
of data collection on each of the visit components are as 
follows:
i. Reported morbidity. Study fieldworkers ask questions 
around morbidities during the pregnancy using the study 
antenatal questionnaire derived from the core variable ta-
bles. These questions are to elicit any occurrence of severe 
maternal morbidity notably haemorrhage (antepartum and 
postpartum), infections, prolonged/obstructed labour, fis-
tula, signs of pre–eclampsia or eclampsia. Since there are 
no current global standards for asking valid and reliable 
questions at the population level on maternal morbidity, 
AMANHI investigators agreed, pre–tested and validated 
questions to elicit maternal morbidities using scientific and 
pragmatic considerations of what data can be elicited from 
women at the community level. For example, for obstetric 
haemorrhage, the study used an adaptation of criteria sug-
gested by Ronsmans [22] based on evidence of possible 
organ failure or life–saving surgical intervention. The lim-
ited evidence suggests that prolonged labour and postpar-
tum haemorrhage (PPH) are particularly poorly reported. 
The standard definition of severity requires a quantification 
of the amount of blood lost (at least 500 ml for spontane-
ous vaginal delivery and 1000 ml for caesarean) to define 
PPH. In the home settings especially for deliveries that take 
place at home, it is difficult to quantify the amount of blood 
lost. AMANHI therefore used pragmatic definitions for 
these outcomes and prescribed these within the core vari-
able table. In enquiring about severe PPH, AMANHI field-
workers are trained to ask about any bleeding from the va-
gina after the birth of the baby, whether the bleeding was 
so much that it not only wet her clothes and the floor but 
also that the woman had to have an “operation” to stop it, 
she collapsed or lost consciousness as a result of or during 
the bleed. Similarly, for each morbidity included in the 
study, fieldworkers elicit information on the timing of on-
set, severity and any interventions received and from who 
this care was received.
ii. Screening for hypertensive disorders of pregnancy. 
Trained fieldworkers directly measure women’s BP and test 
their urine for proteins as part of active assessment for hy-
pertensive disorders of pregnancy using a step–by–step 
protocol agreed across sites. The fieldworker first explains 
the rationale and procedure for the BP measurement and 
the urine sample testing. They make sure the woman sits 
and is made comfortable on a chair and the fieldworker 
places the digital sphygmomanometer on a surface at the 
level of her heart. Her blood pressure is then measured. If 
the pressure is found to be high, a repeat measurement is 
taken after 30 minutes of wait during which period the 
woman rests and is re–assured of the safety of the proce-
dure. The blood pressure measurement is again repeated. 
To collect the urine sample, women are taught how to wipe 
her urethra with clean tissue and provided with a urine col-
lection tube to obtain a sample of their urine for testing. 
Colorimetric methods are used to assess the degree of pro-
teinuria coded from none through to 4 plus. At all visits, 
women with high blood pressure (systolic blood pressure 
>140 mm Hg or diastolic pressure >90 mm Hg) are referred 
to participating health facilities for appropriate care.
If the pregnancy has been aborted/miscarried, they termi-
nate the AMANHI pregnancy follow–up and complete 
postnatal forms for the woman. At the first postnatal visit, 
data are collected on women’s reported morbidity during 
labor, delivery and immediately after birth including care 
seeking and outcomes for mother and baby. Fieldworkers 
also abstract morbidity data and the birthweight of babies 
from available health facility records (hospital folders, post-
natal clinic record cards, etc.) during the postnatal visits.
Also following the realization of the difficulty in obtaining 
reliable data on complications such as hemorrhage through 
women’s self–reports, AMANHI uses an alternative source 
of data to corroborate women’s reported morbidity experi-
ences during home visits – birth attendant accounts of mor-
bidities during childbirth. These data are collected for all 
deliveries conducted by “professional” birth attendants (in-
cluding traditional birth attendants, midwives, nurses and 
doctors).
Birth attendant interviews. Within the first week after ev-
ery birth, fieldworkers identify and interview all delivery 
attendants in health facilities or who assisted five or more 
AMANHI deliveries (whether trained health professional or 
untrained traditional birth attendant – TBA). These inter-
views are done using structured questionnaires to provide 
more detail on women’s morbidity experiences (including 
complications) during labor, delivery and the immediate 
postpartum while under the care of the attendant. These 
interviews are held at the attendants’ home or place of work.
Health facility records review. In a few of the sites, data 
are collected, using a structured questionnaire, on the sub-
set of women who attend health facilities for care during 
pregnancy, childbirth or in the postpartum period and used 
to validate morbidities from women’s and birth attendants’ 
reports. During home visits, data on premature births, in-
tra–uterine growth retardation (IUGR) and mortality out-
comes are also collected from this cohort.
Verbal Autopsies for deaths. Protocols for the conduct-
ing VAs in AMANHI are being published concurrently [23]. 
In summary, fieldworkers conduct verbal autopsies (VAs) 
whenever a woman of reproductive age, her fetus or a neo-
nate dies using standardized tools and procedures. Trained 
field supervisors administer a verbal autopsy tool that has 
been developed using the WHO verbal autopsy tool as tem-
plate. Additional questions were added on from tools used 
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in other computer–based VA software available at the time. 
The supervisors obtain a narrative on the circumstances 
leading to the death, administer a semi–structured ques-
tionnaire to probe for specific signs and symptoms accord-
ing to physiological systems and abstract data from any 
existing records including death certificates to help ascer-
tain the type of death (eg, pregnancy–related or not, neo-
natal death or stillbirth), timing and the cause. Harmonised 
protocols are used by physicians who are selected from the 
respective countries and trained to confirm timing, type 
and to assign causes of these deaths based on principles of 
the International Classification of Diseases.
Outcomes
The main outcome of the study is the prevalence of severe 
acute maternal morbidity (operationally defined to include 
acute problems suffered during pregnancy, through child-
birth to the end of 42 days postpartum). Severe acute ma-
ternal morbidity will include, but is not limited to, pre–(ec-
lampsia), antepartum and postpartum hemorrhage, 
abortion complications, maternal infections, obstructed la-
bor and other complications arising out of these. Denomi-
nators for rate estimates will be total pregnancies or the 
number of women who become pregnant among the co-
hort while those who suffer any severe acute morbidity will 
contribute data to the numerators. In estimating prevalence 
of hypertensive disorders for which AMANHI is directly 
assessing women’s blood pressure and urine proteins at 
baseline (pre–pregnancy levels) and after 42 days postpar-
tum (when those who developed pregnancy–induced hy-
pertension will have returned to baseline states), it will be 
possible to describe a wide spectrum of hypertensive dis-
orders including the classical pregnancy induced hyperten-
sion where women are normotensive pre–pregnancy, de-
velop pregnancy–induced hypertension and return to 
normotensive state after delivery. Care seeking and care 
given for each morbidity will be described.
Sample size considerations
The sample size contributions from each of the sites are as 
shown in Table 3. The 160 000 total participants in the 
study are sufficient for assessing association of severe ma-
ternal morbidity with adverse maternal, fetal and neonatal 
outcomes based on an assumption that all individual sites 
should have adequate power to detect association between 
preterm birth and any morbidity with a prevalence of 7.5% 
or more. Data will be pooled across sites for evaluating 
morbidities with lower prevalence, especially in assessing 
associations with stillbirths and early neonatal deaths.
Data management
Data processing. The study uses paper forms or tablet–
based software for data collection. Forms are independent-
ly double entered by two clerks into study databases with 
stringent range and consistency (R&C) checks with the ex-
ception of Zambia where field monitors collect data using 
forms designed in the TeleForms® system (HP, Cambridge, 
UK). After Zambian supervisors review the forms for com-
pleteness, they are scanned, entered, and exported into an 
Access database. Similar R&C checks are built into the soft-
ware used for data capture at sites using tablets. Data man-
agers within the sites conduct inter–database checks to rec-
oncile and synchronize data from various forms using the 
woman’s unique study ID as the link. Cleaned data are 
saved on special study servers with password–protected 
access to only principal investigators in the sites. They gen-
erate data back–ups on external drives at regular intervals. 
Every three months, sites transfer back–up data to a dedi-
cated server at the WHO/MCA for external quality control 
and storage.
Data analyses. Analyses will be done using Stata® statisti-
cal software package [24]. Incidence of severe maternal 
morbidities will be estimated. The burden of adverse birth 
outcomes will also be estimated. Associations will be inde-
Table 3. Expected number of participants to be enrolled from the AMANHI sites (by region) and precision that can be obtained 
around estimates
region Study country SamPle Size exPected width of 95% ci if Prevalence of morbidity = 2% relative PreciSion
Sub–Saharan Africa DRC 20 000 1.8% to 2.2% ±10%
Ghana 10 000 1.7% to 2.3% ±14%
Kenya 20 000 1.8% to 2.2% ±10%
Tanzania (2 sites) 15 000 1.8% to 2.2% ±11%
Zambia 25 000 1.8% to 2.2% ±9%
Pooled 90 000 1.9% to 2.1% ±5%
South Asia Bangladesh 19 000 1.8% to 2.2% ±10%
India 35000 1.9% to 2.1% ±7%
Pakistan (2 sites) 16 000 1.8% to 2.2% ±11%
Pooled 70 000 1.9% to 2.1% ±5%
CI – confidence interval, DRC – Democratic Republic of the Congo
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ducing preventable maternal mortality [25]. Beyond sur-
vival, another significant statistic is the number of women 
who develop severe acute morbidities and/or severe chron-
ic disabilities that are incompatible with normal physical, 
psychological or economic viability and who are abandoned 
by loved ones, families, friends and society [4,5,7]. One of 
the biggest hurdles to planning and delivery of effective in-
terventions is the dearth of data on maternal morbidities.11 
Good quality data are essential for strategic planning and 
targeting of interventions. In LMICs of sub–Saharan Africa 
and South Asia where resources are limited and a dispro-
portionate burden of severe acute maternal morbidities ex-
ists, evidence–based data–driven strategic prioritization of 
investments and resource allocation to address these is par-
amount [4,6,26,27].
The AMANHI maternal morbidity study will generate reli-
able estimates of severe maternal morbidity from one of the 
largest population–based, multi–country studies in sub–
Saharan Africa and South Asia. AMANHI has many advan-
tages; implementation is being harmonized across sites and 
common definitions of severe maternal morbidity are be-
ing used. This will ensure comparability of data and facili-
tate pooled analyses across sites. The methodological con-
tributions and implications of the AMANHI study design 
for routine data collection platforms such as demographic 
and health surveillance sites is obvious: the need for vali-
dation of definitions of morbidities and harmonization of 
protocols for data collection across sites is urgent. The ab-
sence of these limits data utility in routine surveillance sys-
tems especially where regional or global estimates are to be 
derived from these data. If AMANHI tools can be validated 
within other routine surveillance systems, it is a major con-
tribution to harmonization of data collection tools or if not 
directly, provides the template for developing such valid, 
reliable and globally useful tool for population–based data 
collection systems.
The AMANHI sample size is large and with the active preg-
nancy and birth surveillance allowing for accurate denom-
inators, estimates generated will be precise and reliable. The 
combined comparative advantages of large sample size and 
homogeneity in the data across sites will additionally allow 
for analyses on very rare maternal health outcomes and with 
the linked data on household wealth, inequities in the dis-
tribution of maternal morbidities could be explored.
AMANHI will provide the dual benefit of a unique oppor-
tunity to assess associations between various exposures, 
severe maternal morbidity and adverse pregnancy out-
comes and also address the gap in the availability of qual-
ity data for validation of model–based estimates. The data 
will also form the baseline for generation of more accurate 
estimates of the real impact of severe acute morbidities on 
health and well–being of women after pregnancy and 
pendently explored between various maternal characteris-
tics (confounders) such as socio–economic status, educa-
tional attainment, age, parity, etc. and severe maternal 
morbidity as well as the adverse birth outcomes. The effect 
of exposure to severe acute maternal morbidity on adverse 
birth outcomes will be estimated using appropriate regres-
sion models. Test of interaction will be done to assess effect 
modification of treatment received by study women on as-
sociation between severe maternal morbidities and adverse 
pregnancy, birth and neonatal outcomes.
Quality monitoring
The WHO/MCA centrally coordinates and monitors the 
harmonized implementation, quality of fieldwork and data 
in the AMANHI morbidity study. Individual sites send 
monthly fieldwork progress reports to WHO/MCA, high-
lighting their key challenges. At quarterly intervals, the 
WHO/MCA team run quality control checks on all trans-
ferred data to identify outliers and provide feedback to the 
sites. Data are also reconciled with the monthly fieldwork 
progress reports to check consistency. WHO/MCA sends 
experts to the sites once or twice each year to assess prog-
ress and quality of implementation, provide technical input 
and to enhance the harmonized implementation. They also 
discuss challenges with the sites and provide a detailed re-
port to the WHO/MCA highlighting key issues of benefit 
to and for follow–up with the other sites.
Ethical considerations
All women are individually consented to participate in the 
AMANHI morbidity study. Local and institutional ethics 
committees from all nine sites approved the AMANHI 
study protocols. The Ethics Review Committee of the 
WHO has also approved a combined master protocol with 
components on the role of the WHO/MCA.
Dissemination plan
The results of the study will be disseminated among the 
public health, maternal and newborn health community of 
researchers, policy–makers and program managers. Chan-
nels for dissemination will include peer–reviewed journals, 
print and electronic media and academic presentations 
(oral and poster) at appropriate fora. In each participating 
country, there will be extensive briefing on their country–
specific and overall study results, and the team of research-
ers and stakeholders will discuss implications of the study 
for interventions and programmes in those settings.
Importance of the AMANHI morbidity 
study
Inadequate attention to reducing the burden of maternal 
morbidity may be contributing to the slow progress in re-
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childbirth. Moreover, the implementation strategy informs 
global researchers, academics, funders and institutions on 
how to maximise the utility of data from on–going studies 
that could contribute to answering related questions.
While this contribution of reliable and good quality data 
on maternal morbidity from the AMANHI study to global 
public health is significant in that it will inform policy di-
rection, interventions and programmes, we do recognize 
that it remains the first step needed to create a sustainable 
platform for prioritization and ensuring equitable coverage 
of maternal health interventions for the benefit of both 
mothers and their newborns.
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